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To the Editor,
Helicobacter pylori (H. pylori) infection plays a crucial role in 
causing gastritis and peptic ulcer disease (PUD). To date, despite 
the several regimens proposed, no therapy leads to a 100% 
H. pylori eradication rate (1). As the antimicrobial activity of 
metronidazole is marginally affected by low pH, this drug may 
be highly effective against H. pylori. The European Helicobacter 
Study Group has advised to employ a metronidazole-based triple 
therapy as choice in treating H. pylori infection in relation to 
specific resistance rate in each region (2). Recently, a multicentric 
study revealed that, in Southern Europe, the primary rate of H. 
pylori metronidazole resistance was around 30% (3).
In 2002, we found that in Turin, Northern Italy, a triple therapy 
with metronidazole, amoxycillin and a proton pump inhibitor 
(PPI) for 7 days or for 10 days, achieved an eradication rate 
of 73.5% or 71.6%, respectively. Lengthening the treatment 
conferred no advantages. These values were significantly 
lower compared to those reported earlier (4). In a subsequent 
study with alternative schedules (cefixime plus metronidazole), 
the results did not improve (5). As antibiotic resistance is an 
evolving process, it is mandatory to carry out surveys in order 
to be guided in the therapeutic choice. Hence, in the year 2013 
(January 01 - December 31), we evaluated prospectively the H. 
pylori eradication rate of consecutive naive patients, treated with 
a triple therapy comprising a standard dose of PPI, amoxycillin 1 
g and metronidazole 500 mg twice daily. Results were compared 
with a previous randomized prospective study conducted 10 
years earlier with the same schedule (4). Eradication of H. 
pylori infection was assessed by 13C-urea breath test, performed 
according to the supplier’s instructions (Helicobacter Test, 
INFAI®, Bochum, Germany). The reported sensitivity is 97.9% 
and specificity 98.5%. Samples were analysed for 13C/12C ratio 
with a mass spectrometer (BreathMAT plus, Finnigan, Bremen, 
Germany). Results were expressed as excess ð13CO2 excretion 
per mil: a value >4 delta per mil was considered positive. No 
patient had received PPI or antibiotics in the last 30 days. All 
patients gave their written informed consent. Differences in 
eradication rates were tested with the chi-square test (with Yates’ 
correction for continuity). A p value <0.05 was considered 
significant. The cohort included 66 patients (40 males, mean age 
61.6, range 39-62), 39 of them received a regimen including a 
1-week triple therapy (group I) and 27 were treated with a 10-
day triple therapy (group II). Forty-two of them had a previous 
diagnosis of PUD or gastroduodenal erosions, and the remaining 
of active gastritis. The overall H. pylori eradication rate was 
69.2% (27/39) in group I and 70% (19/27) in group II, without 
significant difference (p=0.96). When compared with the 
prospective study published in the year 2002 (4) no differences 
were observed in the effectiveness of therapy (p=0.81 for 7 days 
and p=0.95 for 10 days) (Table 1). In conclusion, in our area, a 
metronidazole-based treatment regimen for H. pylori eradication, 
although unsatisfactory, is as effective as 10 years ago. 
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TABLE 1. Results of H. pylori eradication regimens 
Treatment H. pylori eradication (%)
 2002 2013 p
PAM
7 days 39/53 (73.5) 27/39 (69.2) 0.81
PAM
10 days 38/53 (71.6) 19/27 (70) 0.95
PAM: proton pump inhibitor, amoxycillin, metronidazole
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